|
Volumn 25, Issue 24, 2015, Pages 5743-5747
|
Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering
a a a a a a a a a a a a a a a a a a a a more.. |
Author keywords
Cell cycle; Centrosome; Oncology; PARP; Tankyrase
|
Indexed keywords
ANTINEOPLASTIC AGENT;
AZ 0108;
AZ 9482;
NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;
NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1;
NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2;
NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 3;
NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 6;
NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;
TANKYRASE;
TANKYRASE 1;
TANKYRASE 2;
UNCLASSIFIED DRUG;
AZD108;
PHTHALAZINE DERIVATIVE;
TNKS PROTEIN, HUMAN;
ANIMAL CELL;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
CENTROSOME;
DRUG BIOAVAILABILITY;
FEMALE;
HELA CELL LINE;
HUMAN;
HUMAN CELL;
HYDROXYLATION;
LIPOPHILICITY;
NONHUMAN;
PHYSICAL CHEMISTRY;
RAT;
STEREOCHEMISTRY;
ANIMAL;
ANTAGONISTS AND INHIBITORS;
BINDING SITE;
CACO 2 CELL LINE;
CHEMISTRY;
CONFORMATION;
DRUG EFFECTS;
METABOLISM;
MICROSOME;
MOLECULAR DYNAMICS;
ORAL DRUG ADMINISTRATION;
PRECLINICAL STUDY;
PROTEIN TERTIARY STRUCTURE;
X RAY CRYSTALLOGRAPHY;
ADMINISTRATION, ORAL;
ANIMALS;
BINDING SITES;
CACO-2 CELLS;
CENTROSOME;
CRYSTALLOGRAPHY, X-RAY;
DRUG EVALUATION, PRECLINICAL;
HELA CELLS;
HUMANS;
MICROSOMES;
MOLECULAR CONFORMATION;
MOLECULAR DYNAMICS SIMULATION;
PHTHALAZINES;
POLY(ADP-RIBOSE) POLYMERASE INHIBITORS;
PROTEIN STRUCTURE, TERTIARY;
RATS;
TANKYRASES;
|
EID: 84947266416
PISSN: 0960894X
EISSN: 14643405
Source Type: Journal
DOI: 10.1016/j.bmcl.2015.10.079 Document Type: Article |
Times cited : (53)
|
References (24)
|